July 15, 2008
Infectious Diseases
Analysis of:
BD Diagnostics' GeneOhm Cdiff test receives CE mark for rapid diagnosis of Clostridium difficile infection | www.labnews.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: BD GeneOhm's recent CE Mark for its molecular diagnostic test for the rapid diagnosis of Clostridium difficile infection will likely intensify the competition between BD and Cepheid. Both companies market tests for the $1 billion dollar Methicillin-Resistant Staphylococcus Aureus (MRSA) market.
Analysis: BD (NYSE: BDX) just received the CE Mark for BD GeneOhm's molecular test for Clostridium difficile. This will enable the company to sell the test in the European market and intensifies the competition between BD and Cepheid (NASDAQ: CPHD).
Both companies offer molecular based tests for Methicillin-Resistant Staphylococcus Aureus. This is a global market that could easily exceed $1 billion annually as hospitals focus on reducing Hospital Acquired Infections (HAIs).
For detailed information on both companies, the fast growing molecular diagnostics and MRSA market segments, please schedule a consult with your GLG representative today.
Analysis: BD (NYSE: BDX) just received the CE Mark for BD GeneOhm's molecular test for Clostridium difficile. This will enable the company to sell the test in the European market and intensifies the competition between BD and Cepheid (NASDAQ: CPHD).
Both companies offer molecular based tests for Methicillin-Resistant Staphylococcus Aureus. This is a global market that could easily exceed $1 billion annually as hospitals focus on reducing Hospital Acquired Infections (HAIs).
For detailed information on both companies, the fast growing molecular diagnostics and MRSA market segments, please schedule a consult with your GLG representative today.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease
www.medicalnewstoday.com
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
www.therapeuticsdaily.com
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents
jco.ascopubs.org
ACE Inhibitor May Ease Cardiac Risks in Marfan's Syndrome
www.medpagetoday.com
Healthways' Guidance Not So Healthy
www.forbes.com
Azilect
September 2, 2008
Byetta Saves Lives
September 2, 2008
The Devil Is in the Details
September 1, 2008
Dangers of Methadone Usage
August 28, 2008
Healthways A Market Downturn and Results
August 26, 2008